ANTX

AN2 Therapeutics, Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website an2therapeutics.com
Employees(FY) 35
ISIN US0373261058

Performance

-8.1%

1W

-8.1%

1M

-37.64%

3M

-86.18%

6M

-88.92%

YTD

-72.58%

1Y

Profile

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, which is in a pivotal Phase 2/3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.

Advanced Technical Analysis

Technical Analysis of ANTX 2024-05-10

Overview:

In analyzing the technical indicators for ANTX over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key indicators, we aim to offer valuable insights and predictions for potential inv...

See more ...

Recent News & Updates

2024-05-14 10:55
ANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q1 2024(Investorplace)
2024-05-14 04:01
AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights(Businesswire)
2024-03-28 11:53
ANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q4 2023(Investorplace)
2024-03-28 04:10
AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights(Businesswire)
2024-03-21 19:00
Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results(Prnewswire)
2024-02-21 15:21
13 Best Falling Stocks To Buy Right Now(Yahoo Finance)
2024-02-12 07:04
UPDATE 1-AN2 Therapeutics to pause lung disease study enrollment(Reuters)
2024-02-12 06:54
AN2 Therapeutics to pause lung disease study enrollment(Reuters)
2024-02-12 06:45
AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease(Business Wire)
2024-02-11 21:03
AN2 Therapeutics Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm(Globenewswire)
2024-02-11 17:45
AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease(Businesswire)
2024-02-01 07:29
We're Not Very Worried About AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Rate(Simply Wall St.)
2024-01-30 16:10
AN2 Therapeutics to Present at Oppenheimer Healthcare Life Sciences Conference(Business Wire)
2024-01-30 03:10
AN2 Therapeutics to Present at Oppenheimer Healthcare Life Sciences Conference(Businesswire)
2024-01-19 06:34
Daily â€“ Vickers Top Buyers & Sellers for 01/19/2024(Argus Research)
2024-01-12 09:02
AN2 Therapeutics Inc Chief Strategy Officer Kevin Krause Sells 7,417 Shares(GuruFocus.com)
2024-01-10 08:50
Recent Price Trend in AN2 Therapeutics, Inc. (ANTX) is Your Friend, Here's Why(Zacks)
2023-11-12 07:06
One AN2 Therapeutics Insider Raised Their Stake In The Previous Year(Simply Wall St.)
2023-11-09 16:05
AN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific Highlights(Business Wire)
2023-11-09 03:05
AN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific Highlights(businesswire)
2023-11-06 08:50
AN2 Therapeutics, Inc. (ANTX) Is a Great Choice for 'Trend' Investors, Here's Why(Zacks)
2023-11-06 07:00
AN2 Therapeutics to Present at Upcoming Investor Conferences(Business Wire)
2023-11-05 18:00
AN2 Therapeutics to Present at Upcoming Investor Conferences(businesswire)
2023-10-18 07:00
AN2 Therapeutics Signs License Agreement with the University of Georgia Research Foundation to Develop Novel Boron-Based Therapy for Chagas Disease(Business Wire)
2023-10-17 19:00
AN2 Therapeutics Signs License Agreement with the University of Georgia Research Foundation to Develop Novel Boron-Based Therapy for Chagas Disease(businesswire)
2023-10-16 06:43
AN2 Therapeutics, Inc. (NASDAQ:ANTX) stock most popular amongst individual investors who own 29%, while private equity firms hold 27%(Simply Wall St.)
2023-10-11 00:01
AN2 Therapeutics to Present New Data for Epetraborole at IDWeek 2023(Business Wire)
2023-10-10 12:01
AN2 Therapeutics to Present New Data for Epetraborole at IDWeek 2023(businesswire)
2023-09-26 21:40
Is Adagene (ADAG) Outperforming Other Medical Stocks This Year?(Yahoo Finance)
2023-09-25 19:00
AN2 Therapeutics Signs Grant Agreement to Discover Novel, Boron Based Therapies for Tuberculosis and Malaria(Yahoo Finance)

Page 1 of 3

previousnext